Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Oct 22;63(11):e01347-19.
doi: 10.1128/AAC.01347-19. Print 2019 Nov.

Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?"

George Sakoulas  1   2 , Matthew Geriak  3 , Fadi Haddad  4 , Warren Rose  5 , Kerry LaPlante  6 , Marcus Zervos  7 , Ravina Kullar  8 , Victor Nizet  2
Affiliations
Comment

Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?"

George Sakoulas et al. Antimicrob Agents Chemother. .
No abstract available

PubMed Disclaimer

Figures

FIG 1
FIG 1
Retrospective survival analysis of the first 11 patients receiving combination therapy with daptomycin plus ceftaroline (n = 11) at our hospital as part of a drug utilization evaluation compared to matched patients (1:2 ratio based on source of bacteremia, age, and renal function) receiving vancomycin monotherapy (n = 22). These were all pretrial patients. The P values for the difference in mortality at different times follow: after 30 days, P = 0.2; after 60 days, P = 0.14; after 1 year P = 0.06.
See this image and copyright information in PMC

Comment on

References

    1. Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. 2019. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63:e02483-18. doi:10.1128/AAC.02483-18. - DOI - PMC - PubMed
    1. Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. 2012. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 25:362–386. doi:10.1128/CMR.05022-11. - DOI - PMC - PubMed
    1. Juul FE, Garborg K, Bretthauer M, Skudal H, Øines MN, Wiig H, Rose Ø, Seip B, Lamont JT, Midtvedt T, Valeur J, Kalager M, Holme Ø, Helsingen L, Løberg M, Adami HO. 2018. Fecal microbiota transplantation for primary Clostridium difficile infection. N Engl J Med 378:2535–2536. doi:10.1056/NEJMc1803103. - DOI - PubMed
    1. Pujol M, Miro JM, Shaw E, et al. . 2018. Daptomycin plus fosfomycin versus daptomycin monotherapy for methicillin-resistant Staphylococcus aureus bacteremia. A multicenter, randomized clinical trial, abstr LB3. IDWeek 2018. https://idsa.confex.com/idsa/2018/webprogram/Paper74232.html#. - PMC - PubMed
    1. Hall P. 2019. Highlights from ECCMID 2019. Lancet Infect Dis 19:582. doi:10.1016/S1473-3099(19)30223-3. - DOI - PubMed